Polycythemia screening: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia}} | {{Polycythemia}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}}{{Debduti}} | ||
==Overview== | ==Overview== | ||
Line 31: | Line 31: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hematology | [[Category:Hematology]] | ||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} |
Revision as of 20:51, 24 September 2020
Polycythemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polycythemia screening On the Web |
American Roentgen Ray Society Images of Polycythemia screening |
Risk calculators and risk factors for Polycythemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]